Olema Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in targeted therapies for breast cancer, has released its financial and operating results for the second quarter ending June 30, 2025. The company reported a net loss of $43.8 million for the quarter, compared to a net loss of $30.4 million in the same period in 2024. This increase in net loss is attributed to a one-time milestone payment of $10 million to Aurigene and heightened research and development expenditures linked to ongoing late-stage clinical trials for palazestrant and the advancement of OP-3136. GAAP research and development expenses rose to $43.9 million, up from $29.1 million in the previous year, while GAAP general and administrative expenses decreased to $4.0 million from $4.4 million due to a reduction in stock-based compensation expenses. Olema's cash, cash equivalents, and marketable securities stood at $361.9 million as of June 30, 2025. Significant operational updates include selecting a 90 mg once-daily dose of palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and the forthcoming OPERA-02 Phase 3 trial in combination with ribociclib. The OPERA-01 trial continues to enroll participants with top-line data expected in the second half of 2026, and the OPERA-02 trial is set to begin in the third quarter of 2025. Additionally, mature data from a Phase 1b/2 study of palazestrant in combination with ribociclib will be presented at ESMO 2025.